Central Nervous System Clinical Trials

We have the EXPERIENCE You Need to Manage Your CNS Clinical Trial

With specific expertise in CNS, cardiovascular, and oncology, among other therapeutic areas, Clinipace Worldwide has managed over 90 contract research projects conducted globally at almost 3,000 sites with 100,000 patients.

Clinipace offers unmatched expertise in providing emerging and mid-tier biopharmaceutical and medical device firms technology-driven contract research services. With more than 80% of our clinical operations staff having seven or more years of relevant industry and trial experience we provide exceptional operational, regulatory, and scientific guidance and oversight to your trial.

Our central nervous system clinical trial experience includes managing wide-ranging CNS projects, including:

  • Phase 3 Cervical Dystonia and Cosmetic Use of Botulinum Toxin


  • Phase 3 Multiple Sclerosis


  • Phase 4 Autism


  • Registry: Psychiatry

How Can We Help You?

New advancements in the treatment of CNS-related disorders including Multiple Sclerosis, Alzheimer’s, and Parkinson’s disease make this one of the largest and fastest growing therapeutic areas of the pharmaceutical market.  However, success rates within CNS drug development average lower than many other categories.  While there are many contributing factors, methodologies behind the clinical integrity and reliability of clinical data could be a major cause making your choice of clinical research organization even more important.

Given the high stakes involved, running a successful CNS trial can result in high returns.  Before embarking on a CNS trial, teaming with the right CRO can reduce trial complexity and result in a more efficient trial.  There are many special considerations you should take into account, including:

  • How to determine the best eligibility criteria and stick to it


  • How to choose the right investigator to increase enrollment (this often means going outside of the US to get the best participants for your trial)


  • Why you need to consider the role of technology in reducing trial complexity and running a more efficient trial:

    • - Partnering with a CRO to monitor which sites are getting patients on board and whether they meet eligibility requirements

    - Partnering with a CRO to keep down prices through licensed technology

    - Increasing trial efficiency through centralized data, standardized processes, branded methodology, and integrated site management with monitoring and regulatory aspects

    - Collecting and analyzing real-time data to track study results and implement corrective action, if required

  • How to develop and track patient treatment plans

Clinipace Central Nervous System Clinical Trial News

Thursday, April 27, 2010
Clinipace Worldwide to Manage Clinical Trials for Four New Clients

Following industry trends crediting oncology products as one of the largest drivers of clinical development growth, Clinipace Worldwide has been granted two oncology-related trials, one Phase 2 and one Phase 3 trial. Other recently awarded projects include a Phase 1b rheumatoid arthritis study and Phase 3 gastroenterology trial.

Friday, March 5, 2010
With drug pipeline brimming, outlook for CROs brightens (Triangle Business Journal)

Olson is skeptical about growth in the number of new drugs under development. He says some companies are flattening or even shrinking their R&D budgets. “If that’s the case for the industry, then CRO growth is going to have to come from increased outsourcing penetration because the pie won’t be getting larger, at least for now,” he says. Olson says oncology products are the single largest driver of the growth of compounds in clinical development. Cardiovascular and central nervous system compounds are also significant contributors to growth.

Wednesday, May 06, 2009
Clinipace Expands its Team of Clinical Development Experts

Williams explained, "Over the years, Clinipace and our team have conducted and provided oversight for dozens of clinical studies. While not specializing in any one therapeutic area, we have significant experience in managing trials and registries across North America with a focus on Cardiovascular, Central Nervous System, Psychiatry, Oncology, Gastrointestinal disorders, Dermatology, Biologics and Immunology. By operationalizing the trial protocols with our technology-driven model, sponsors are assured that our experienced clinical trial specialists in project management, clinical and site monitoring, data management, and biostatistics deliver the solution and budget to fit any trial or project."

September 17, 2008
Clinipace Awarded Ten New Projects Valued at More than $1.0 Million

After a successful capital infusion from Hatteras Venture Partners in late 2007 and increasing demand for affordable software within the mid-market, Clinipace has expanded its staff by over 50 percent, primarily within its sales and services teams. In recent months, Clinipace has signed five new customers, including Inspire Pharmaceuticals, VaxInnate, SHS International, and the Crohn Colitis Foundation of America. It was also awarded five additional software projects from existing customers.

May 1, 2008
Neuroscience Spine Institute and Department of Emergency Medicine at Carolinas Medical Center Successfully Completes Research Project with Web-Based Software from Clinipace

Andrew Asimos, MD, Director of Emergency Stroke Care at Carolinas Medical Center in Charlotte, NC and site investigator for the North Carolina Collaborative Stroke Registry (NCCSR), recognized that the registry could serve as the backbone for additional research, particularly on patients who have a Transient Ischemic Attack (TIA), also called a mini-stroke. Dr. Asimos wanted to validate guidelines for risk -stratifying patients who experience a TIA that purport to predict whether these patients would go on to have a full-fledged stroke in the short term.

June 27, 2006
Clinipace Wins National Antiphospholipid Syndrome Registry Managed By UNC-Based Thurston Arthritis Research Center

May 17, 2005
Clinipace and UNC-CH Partner to Launch NC Collaborative Stroke Registry

What Our Customers Have To Say


“Each hospital needed to follow up with patients twice during the study period. Utilizing TEMPO’s built-in workflow engine and reporting tools, we were able to automatically assign follow-up tasks and provide reminders to each stroke program coordinator. Since information was able to reach the research team in real-time, team members could quickly run reports [within their appropriate permissions] to keep up-to-speed on enrollment and follow-up milestones. Having instant access to data made managing the project very easy.”

Andrew Asimos, MD, Director of Emergency Stroke Care at the Carolinas Medical Center in Charlotte, NC, and site investigator for the North Carolina Collaborative Stroke Registry (NCCSR) ®